SOUNDTRACK-B: A phase 2 single-arm study to evaluate the efficacy and safety of surovatamig (AZD0486) in relapsed or refractory B-cell non-Hodgkin lymphoma
Chan Y. Cheah(The University of Western Australia), Jing‐Zhou Hou(Center for Cancer and Blood Disorders), Catherine Thiéblemont(Université Paris Cité), Dai Maruyama(National Cancer Center), Monique Menzies Wojtowicz(Macquarie University), Robin Lesley(San Francisco Public Library), Martin Hutchings(University of Copenhagen), Wendy Chang, Mihail Obrocea(AstraZeneca (Japan)), Max S. Topp(Universitätsklinikum Würzburg), Marlene Zuraek(San Francisco Public Library), Won-Seog Kim(Samsung Medical Center), Azadeh Shohoudi(AstraZeneca (Japan))
Cited by 1
Related Papers
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2020|1.9k
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
|The Lancet Oncology|2014|1.3k
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study
|The Lancet|2021|795
Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2022|718
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
|Nature Medicine|2021|523